Johnj, since you are KRAS mutated, has your oncologist mentioned Onvansertib? It’s new but fast tracked in the trials so I think oncologists can request it. It’s given in complement to Folfiri and Avastin and is specifically for KRAS MSS patients, and quite promising.
Another weapon in the arsenal, should lonsurf have too many side effects or not be as efficient as hoped.
Good luck to you and jep’s husband with the new treatments XXXXXXXX
Wife of Dx 04/18 (51 yo). MSS, KRAS G12A
No primary (involuted?)
Lytic tumor L4 vertebrae, EBRT 04/18, SBRT 02/19
Resect small intestine 05/18 (no cancer - Crohn's)
Failed adjuvant Xelox
Folfiri + Avastin 03/19 to 01/20
6.7 cm left adrenal mass 03/19, successful resection 02/20
CEA since 03/19: high 58, low 3.2, now 4.4
Scan 03/19: Multiple small lung nodules up to 5mm
Scan 12/19: one 1mm stable nodule
PET 04/20 uptake by L4
L3-L4-L5 fusion surgery and residual tumor removal 05/20